LEGN.NASDAQLegend Biotech CORP

SCHEDULE 13G/A: T. Rowe Price Associates Updates Passive Stake in Legend Biotech to 3.7%

Sentiment:

Beneficial Ownership Disclosure

📋All filings for Legend Biotech CORP
🔒Login to Follow

T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, disclosing a 3.7% beneficial ownership stake in Legend Biotech Corp-ADR as of December 31, 2024.

Worse than expectedThe filing of an Amendment No. 2 to Schedule 13G, reporting a 3.7% stake, suggests that T. Rowe Price Associates, Inc. has reduced its beneficial ownership in Legend Biotech Corp-ADR to below the 5% threshold. A reduction in stake by a major institutional investor can be interpreted as a negative signal by the market.

Summary

  • T. Rowe Price Associates, Inc., an investment adviser based in Baltimore, Maryland, has filed an Amendment No. 2 to its Schedule 13G regarding its beneficial ownership in LEGEND BIOTECH CORP-ADR.
  • As of December 31, 2024, T. Rowe Price Associates, Inc. beneficially owns an aggregate of 6,808,023 American Depositary Receipts (ADRs) of Legend Biotech Corp.
  • This aggregate amount represents 3.7% of the total class of Legend Biotech Corp-ADR securities.
  • The firm holds sole voting power over 6,481,031 shares and sole dispositive power over 6,808,081 shares, with no shared voting or dispositive power.
  • The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the implied reduction in a significant institutional investor's stake below a key reporting threshold, which can be perceived as a lack of conviction or a portfolio rebalancing away from the issuer.

Negatives

  • The filing of an Amendment No. 2 to Schedule 13G, reporting a 3.7% stake, implies that T. Rowe Price Associates, Inc. has reduced its beneficial ownership in Legend Biotech Corp-ADR to below the 5% threshold, which could be perceived negatively by the market as a reduction in a significant institutional investor's position.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of an institutional investor's passive stake and does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology sector. It reflects an investment decision by T. Rowe Price Associates, Inc. regarding its portfolio allocation.

Stakeholder Impact

  • Shareholders: The implied reduction in stake by a major institutional investor like T. Rowe Price Associates, Inc. could be interpreted as a negative signal, potentially influencing investor sentiment and the company's stock price.

Key Dates

DateDescription
12/31/2024Date of event which requires the filing of this statement (reporting period end date).
02/14/2025Date the Schedule 13G Amendment No. 2 was signed.

Keywords

SEC filing, Schedule 13G, beneficial ownership, institutional investor, T. Rowe Price Associates, Legend Biotech Corp, ADR, passive investment, equity stake

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.